Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)



Status:Terminated
Conditions:Brain Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/17/2019
Start Date:April 2011
End Date:June 16, 2014

Use our guide to learn which trials are right for you!

Phase II Trial for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) Treated With Gliadel Followed by Concurrent Radiation Therapy, Temodar and Avastin, Then Followed by Avastin and Temodar Post-Radiation

The purpose of this study is to determine the safety and effectiveness of Gliadel wafers at
the time of surgery, followed by the combination of radiation, Temodar, and Avastin, and then
the combination of Avastin and Temodar, after radiation is complete, on malignant brain
tumors.

About six weeks after surgery, subjects will begin standard radiation therapy, a fixed dose
of Avastin every 2 weeks, and daily Temodar for the six and a half weeks of radiation.
Beginning 2-3 weeks after the last radiation therapy, subjects will be given the same fixed
dose of Avastin intravenously (through the vein) every 14 days. They will also be given a
higher dose of oral Temodar to take daily the first 5 days of each 28-day study cycle.


Inclusion Criteria:

- Patients must have a MRI consistent with a WHO grade IV primary malignant glioma
(glioblastoma multiforme or gliosarcoma), and be candidates for surgical resection
with Gliadel wafer placement. Patients have to be within 6 weeks of the last major
surgical procedure.

- Age ≥ 18 years

- Candidates for Gliadel

- If a prior procedure was done, an interval of at least 2 weeks and not > 8 weeks
between prior major surgical procedure and study enrollment

- No prior radiotherapy or chemotherapy for a brain tumor

- Karnofsky > 60%

- Hemoglobin ≥ 9.0 g/dl, ANC ≥ 1,500 cells/microliters, platelets ≥ 125,000
cells/microliters

- Serum creatinine ≤ 1.5 mg/dl, serum SGOT and bilirubin ≤ 1.5 times upper limit of
normal.

- Signed informed consent approved by the Institutional Review Board

- If sexually active, patients must agree to use appropriate contraceptive measures for
the duration of the study and for 6 months afterwards as stated in the informed
consent.

Exclusion Criteria:

- Pregnancy or breast feeding.

- Co-medication that may interfere with study results; e.g. immuno-suppressive agents
other than corticosteroids.

- Active infection requiring IV antibiotics.

- Prior treatment with radiotherapy or chemotherapy for a brain tumor, irrespective of
the grade of the tumor.

- Evidence of > grade 1 CNS hemorrhage on baseline MRI or CT scan.

- Prior treatment with Avastin for any condition

- Prior, unrelated malignancy requiring active treatment with the exception cervical
carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the
skin

Avastin-Specific Exclusion Criteria:

- Inadequately controlled hypertension (defined as systolic blood pressure >150 and/or
diastolic blood pressure > 100 mmHg)

- Prior history of hypertensive crisis or hypertensive encephalopathy

- New York Heart Association (NYHA) Grade II or greater congestive heart failure

- History of myocardial infarction or unstable angina within 6 months prior to study
enrollment

- History of stroke or transient ischemic attack within 6 months prior to study
enrollment

- Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or
recent peripheral arterial thrombosis) within 6 months prior to study enrollment

- History of hemoptysis (≥ ½ teaspoon of bright red blood per episode) within 1 month
prior to study enrollment

- Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic
anticoagulation)

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to the first Avastin infusion or anticipation of need for major surgical
procedure during the course of the study

- Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days prior to study enrollment

- History of abdominal fistula, gastrointestinal perforation within 6 months prior to
study enrollment

- Serious, non-healing wound, active ulcer, or untreated bone fracture

- Proteinuria at screening as demonstrated by urine dipstick for proteinuria ≥ 2+
(patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should
undergo a 24-hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to
be eligible).

- Known hypersensitivity to any component of Avastin

- Pregnant (positive pregnancy test) or lactation. Use of effective means of
contraception (men and women) in subjects of child-bearing potential
We found this trial at
1
site
Durham, North Carolina 27710
?
mi
from
Durham, NC
Click here to add this to my saved trials